Durable Response to Sotorasib (Lumakras) Seen in NSCLC: CodeBreaK100

Saruparib, a selective PARP1 inhibitor, showed activity in patients with homologous recombination repair-deficient breast cancers, according to new data.

With longer follow-up and pooled data, adagrasib plus cetuximab continue to show clinical activity in KRAS G12C-mutated colorectal cancer.

Staggered dosing of chemotherapy and olaparib increased tolerability and improved outcomes for patients with germline BRCA-mutated breast cancer.

Patients who responded to an investigational mRNA vaccine continue to show strong T-cell responses, and many remain recurrence-free at three years.

Novel biomarkers are crucial for personalized cancer treatments that maximize patient outcomes. Timothy A. Yap discusses recent key research.

Patients of African descent with CRC were found to have fewer actionable treatment targets. Henry Walch, MS, explains what this means for care.

Perioperative immunotherapy may change the approach for resectable NSCLC. John V. Heymach, MD, PhD, discusses key issues, including safety and what’s next.

“The combination of a PARP inhibitor and an ATR inhibitor provides a rational approach to improve PARP inhibitor efficacy,” one investigator said.

From cancer vaccine efficacy to developments in lung cancer, Roy S. Herbst, MD, PhD, discusses practice-changing highlights from the 2023 AACR Annual Meeting.

“REGN5459 showed early, deep, and durable responses in patients with relapsed or refractory MM who are heavily pretreated,” a study author said.

Adding pembrolizumab to gemcitabine and cisplatin improved survival in patients with untreated metastatic or unresectable biliary tract cancer. What’s next?

Given the dismal survival rate in malignant pleural mesothelioma, “remarkable” results for two new treatment options are being met with excitement and caution.